Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study
| Status: | Archived |
|---|---|
| Conditions: | Depression, Schizophrenia, Major Depression Disorder (MDD), Neurology, Psychiatric, Bipolar Disorder, Autism |
| Therapuetic Areas: | Neurology, Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | October 2009 |
| End Date: | October 2011 |
The purpose of this study is to get a better understanding of the side effect burden and
identify predictors of psychotic, mood and aggressive disorders in children and adolescents.
The study's primary aim is to identify genetic risk factors for weight gain and metabolic
abnormalities.
Participants will be evaluated for biological and genetic risk factors for nutritional and
metabolic adverse effects associated with SGAPs (second generation antipsychotics) during 4
visits over 12 weeks. Participants will also be evaluated at month 6, 9, and 12. This
study does not involve treatment for participants. Treatment of subjects enrolled in this
study will be determined by their clinician and will remain unaffected by participation in
this observational minimal risk study.
We found this trial at
1
site
101 Manning Dr
Chapel Hill, North Carolina 27599
Chapel Hill, North Carolina 27599
(919) 966-4131
University of North Carolina Hospital at Chapel Hill The UNC Health Care System is a...
Click here to add this to my saved trials
